Company
Headquarters: Acton, MA, United States
Employees: 2,300
CEO: Ms. Shacey Petrovic
$19.44 Billion
USD as of Jan. 1, 2025
Company | Market Cap (USD) |
---|---|
Abbott | $213.72 B |
Stryker | $150.01 B |
Boston Scientific Corporation | $149.80 B |
Medtronic | $114.44 B |
Shenzhen Mindray Bio-Medical Electronics Co. Ltd | $47.37 B |
Company | Market Cap (USD) |
---|---|
Lilly | $689.42 B |
Novo Nordisk | $622.07 B |
UnitedHealth Group | $487.54 B |
Johnson & Johnson | $353.05 B |
AbbVie | $301.60 B |
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Top 1-year algo backtest: +327.04%
$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Last Financial Reports Date | Sept. 30, 2024 |
Revenue TTM | $1.98 B |
EBITDA | $415.5 M |
Gross Profit TTM | $1.38 B |
Profit Margin | 21.22% |
Operating Margin | 16.20% |
Quarterly Revenue Growth | 25.70% |
Insulet Corporation has the following listings and related stock indices.
Stock: NASDAQ: PODD wb_incandescent
Stock: FSX: GOV wb_incandescent